Join
Live feed
·
PRReleasevia Quantisnow
AtaiBeckley Inc. logo

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

ByQuantisnow·Wall Street's wire, on your screen.
ATAI· AtaiBeckley Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ATAI (AtaiBeckley Inc.) and more on Quantisnow.